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Abstract
Alternative specimens have been occasionally considered as substitutes for whole blood for post-
mortem toxicology testing. We studied the applicability of vitreous humor, and evaluated whether
it would be suitable to replace (or augment) whole blood for routine drug screening. Results showed
that from 51 autopsy cases, we were able to identify an aggregate of 209 findings in whole blood
compared with 169 in vitreous. The total number of compounds identified was 71 for whole blood
and 60 for vitreous humor. Quantitative analysis showed that whole-blood concentrations of trazo-
done were several fold higher than vitreous humor concentrations (1.42 ± 0.57 vs. 0.15 ± 0.05 mg/L,
respectively) and similar results were also obtained for diazepam (0.37 ± 0.06 vs. 0.13 ± 0.01, respect-
ively). For other drugs such as oxycodone, hydrocodone and doxylamine, a trend suggesting higher
concentrations in vitreous humor vs. whole blood was observed; however, this was not significant.
Our results are consistent with the limited work of other investigators, and suggest that vitreous
humor could be an appropriate matrix for drug screening in postmortem toxicology.
Introduction
Mass spectrometry (MS) has gained a leading role as the technique
of choice used in forensic toxicology. The choice of specimen for
MS analysis includes blood, tissue, urine, saliva, hair and vitreous
humor. For quantitative results, blood has been the primary matrix
utilized in postmortem toxicology (1). However, one substantial
issue with interpreting concentrations of drugs in blood specimens is
that postmortem redistribution can change concentrations after death
(2). Vitreous humor has been proposed as an alternative matrix to
blood for postmortem toxicology testing (3, 4). Vitreous fluid offers
several advantages over other specimens such as longer sample stabil-
ity and easier pretreatment (1). However, major limitations that
have hampered the use of vitreous fluid as an alternative matrix for
postmortem toxicological analyses include limited specimen volume,
and the blood–retinal barrier that limits the passage of drugs in
and out of the vitreous fluid (5). Some reports have used targeted ana-
lysis to compare drug concentrations between whole blood and
vitreous fluid, such as for oxycodone (6) designer amphetamines (7),
benzodiazepines (1) cocaine (8, 9), 11-nor-9-carboxy-Δ9-tetrahydro-
cannabinol (10) and opiate (9), but there are no reports comparing
broad-spectrum drug screening results between whole blood and
vitreous fluid.
Electron impact gas chromatography (GC)–MShas been tradition-
ally used for postmortem forensic toxicological studies. When utiliz-
ing GC–MS, full scan spectra from the analyte are matched against
a pre-existing library and a score which describes how well the two
spectra match is generated. The efficiency of GC when combined
with simple extraction protocols and a large spectral library has estab-
lished GC–MS as a commonly used technique for postmortem drug
identification.
In this study, GC–MS was employed to investigate whether vitre-
ous fluid could serve as an alternative matrix for postmortem toxicol-
ogy studies for broad-spectrum postmortem drug screening. Results
obtained in vitreous were compared with those of whole blood.
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Experimental methods
Sample collection
Whole-blood and vitreous fluid samples from 51 autopsy cases were
collected during forensic autopsies. Peripheral blood (∼20 mL) was
drawn from the left common iliac vein (blood returning from the leg
and visually identified in the pelvis at autopsy) and stored in standard
glass tubes containing sodium fluoride (100 mg) and potassium oxal-
ate (20 mg). Vitreous humor samples (∼5 mL) were pulled from both
eyes with a syringe and stored in a glass tube without preservative. All
specimens were stored at 4°C.
Detection of drugs in whole blood was performed through a vali-
dated method used routinely in autopsy cases. Drug-free porcine
blood or human drug-free pooled vitreous humor was used as the al-
ternative matrix for quality control (QC) and calibrator preparation.
An initial investigation was performed to assess the validity of re-
placing vitreous fluid with water or phosphate-buffered saline (pH
7.4) for calibrators and QC material. However, due to unsatisfactory
recovery studies (data not shown), none of these matrixes were appro-
priate to substitute vitreous fluid. Consequently, a pool of human
drug-free vitreous fluid was collected to prepare calibrators and QC.
Materials
Dichloromethane, methanol, ethyl acetate and isopropanol were
EMD Chemicals OmniSolv grade, purchased through VWR Inter-
national (Radnor, PA, USA). Ammonium hydroxide (ACS), cyclizine
hydrochloride and glacial acetic acid (ACS) were obtained from VWR
International. Zinc sulfate heptahydrate (certified ACS) was obtained
from Fisher Scientific (Pittsburgh, PA, USA).
Sample preparation
The procedure for drug screeningwas as previously described (11, 12).
Calibrators, patient samples and QC were fortified at the appropriate
concentration and the final volumewas made up to 2 mL in the appro-
priate matrix. To this was added 200 μL of internal standard (1.0 μg:
cyclizine) and 200 μL of 2% ascorbic acid. Samples were mixed, pre-
cipitated with 5 mL of zinc sulfate (5% methanolic solution), centri-
fuged at 2,400 g for 10 min and the supernatant was treated with
4 mL of sodium acetate (pH 6.0) buffer.
The supernatant was passed through an SPE column (SPEWare,
Baldwin Park, CA, USA) which was initially preconditioned with
3 mL of methanol, 3 mL of distilled water and 2 mL of sodium acetate
(pH 6.0). Following sample extraction, the column was washed with
3 mL of distilled water, 2 mL of 100 mmol/L of acetic acid and 3 mL
of methanol. Cartridges were dried and the analytes were elutedwith a
mixture of dichloromethane : isopropanol : ammonium hydroxide
(78 : 20 : 2). Samples extracts were then dried under nitrogen and re-
constituted with 150 μL of ethyl acetate for GC–MS analysis.
GC–MS analysis
One microliter of sample was injected into 7890A GC–MS system
(Agilent Technologies, Santa Clara, CA, USA) consisting of a 15-m,
0.25-mm diameter and 0.25-μm film thickness analytical column
(Zebron, ZB-5MS; Phenomenex, Torrance, CA, USA). Helium was
used as the carrier gas with a flow rate of 1.1 mL/min. The inlet tem-
perature of the GC was 250°C with an initial oven temperature of 85°
C which increased to 170°C at the rate of 40°C/min (held 4 min), then
40°C/min to 190°C (held 5 min) and finally 10°C/min up to 300°C
(held 7 min). The MS Aux was 280°C. The mass selective detector
(5975C, Agilent Technologies) was set in scan mode with a solvent
delay of 2.64 min. The MS mass range was 43.00–550.00 amu, the
threshold was 150 counts and the sampling rate was 2 (2N).
Data analysis
By using peak area ratios (including IS), the procedures employed en-
abled quantification of several commonly detected compounds by the
utilization of appropriate calibration curves. The compounds that
could be quantified (or semi-quantified) were split into three panels
(Supplementary Table I). Panels A and B consisted of a five-point cali-
bration curve (0.1–1.0 mg/L), whereas Panel C consisted of a single-
point calibrator (generally 0.50 mg/mL) which only provided a semi-
quantitative estimate of drug concentrations. Relevant drugs from
Panel C were routinely quantified with a second specific analytical
technique. For drug Panels A and B, samples with low concentrations
that were unlikely to be related to cause of death (toxicologically insig-
nificant) were routinely reported directly from the results obtained
with this screening procedure.
Data were analyzed using the analyst software (Agilent Technolo-
gies). Peak identification was determined by relative retention time
(relative to the internal standard ±0.08), and then mass spectral
matching from a commercial MS library and/or SWGDRUG mass
spectral library (http://www.swgdrug.org; at least 70% match).
Validation
During each run, two different QC samples fortified in vitreous fluid at
0.5 mg/L were run (QC A and QC B; Supplementary Table II) in du-
plicates. The calibration curves were linear and the concentration of
QC samples was expected to be within 20% of the 0.50 mg/L target.
Statistical analysis
Data were analyzed by the GraphPad prism software (La Jolla, CA,
USA) using nonparametric two-tailed t-test. A value of P < 0.05 was
considered statistically significant.
Results and discussion
To the best of our knowledge, only one other laboratory has per-
formed a broad-spectrum drug screening study, and compared drug
concentrations between urine and vitreous humor using an LC-
time-of-flight (TOF) system (3). This earlier investigation reported
that the number of drugs in vitreous fluid and the concentration of
such drugs were lower than urine (3). We compared the number
of drugs that were identified in whole blood with that determined in
vitreous fluid from the same decedents. Furthermore, for those drugs
that were able to be quantified, we also compared their relative
concentrations. The aggregate number of findings in whole blood
and vitreous fluid was 209 and 169, respectively. The total number
of different compounds identified was 71 for whole blood and 60
for vitreous. Results are given in Table I.
Some drugs proved to be more difficult to identify in vitreous
humor compared with whole blood. We applied criteria that if a
drug was identified twice in whole blood and if it was identified at a
rate of 50%or lower in vitreous, then we considered it as difficult to be
identified in vitreous humor. Using these criteria, drugs that were dif-
ficult to identify included: 7-aminoclonazepam, benztropine, cyclo-
benzaprine, morphine, norvenlafaxine, phenytoin, promethazine,
zolpidem and zopiclone. Possible explanations for difficulty in detect-
ing these drugs include: low concentrations of drugs in vitreous humor
compared with whole blood, inability of the drug to cross the blood–
retina barrier, drug redistribution to other tissues than vitreous humor
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and matrix effects. Since the number of specimens included in this
study was small, a larger study would be necessary to further deter-
mine if such drugs are routinely difficult to identify in vitreous humor.
A comparison of the concentrations for those compounds that
were quantified (n≥ 3) was then performed. A statistically significant
increase in the concentration of trazodone and diazepamwas observed
in whole blood when compared with vitreous fluid (Figure 1), with a
trend being observed for fluoxetine (however, this was not significant).
A trend suggesting higher drug concentrations in vitreous fluid com-
pared with whole blood was observed for oxycodone, hydrocodone
and doxylamine; however, these results were not significant. The
small non-statistical increase in oxycodone concentrations is consist-
ent with other investigations which have found a ratio of 1.16 in vit-
reous humor/blood (6). Pelander et al. (3) investigated broad drug
screening in vitreous by using LC-TOF–MS and compared it with
urine. In that study, the authors were able to identify 45 compounds
and 24 metabolites in vitreous humor compared with 55 compounds
and 39 metabolites in urine. The total number of findings in vitreous
was 245 compared with 376 in urine. These findings were similar to
the findings of the present study where there was a reduction in the
number of drugs identified when analyzing vitreous humor compared
with whole blood.
Only some of the drugs that were detected could be quantified. In
order for a drug to be quantified, it had to meet the detection criteria
outlined in the methods; in addition, the concentration of the drug had
to be within the concentration range of the calibrators. Our results
showed that the concentrations of trazodone and diazepam were sev-
eral fold lower in vitreous fluid compared with whole blood. Trazo-
done has high plasma protein binding (13), which could account for
the higher concentrations observed here. Diazepam and other benzo-
diazepines have also been found to have lower concentrations in vitre-
ous compared with whole blood (1).
There are a number of limitations to our study. First, our vitreous
assay was based on an analytical method developed for measuring
drugs in whole blood and we did not perform an extensive validation
of using the technique for vitreous fluid. For validation of the vitreous
fluid assay, we established that calibration curves were linear and that
the QC samples demonstrated a similar response (area) as blood QC
with appropriate recovery of target concentrations. However, the ex-
traction efficiency of all compounds was not specifically determined.
In addition, detection and quantification limits were not determined
and remain the subject of additional investigations. Second, this
‘screeningmethod’ has not been optimized for the detection of opiates,
which may help explain why morphinewas a difficult drug to identify.
Table I Frequency of Drug/Metabolite Occurrence in 51 Autopsy Cases
Compound Number of findings
in blood
Number of findings
in vitreous
Compound Number of findings
in blood
Number of findings
in vitreous
7-Aminoclonazepam 2 0 Lidocaine 4 3
Acetaminophen 2 2 Meprobamate 1 1
Alprazolam 6 5 Methadone 3 3
Amitriptyline 3 3 Metronidazole 1 1
Benzoylecgonine 2 2 Mirtazapine 5 5
Benztropine 2 0 Mitragynine 1 1
Brompheniramine 1 1 Morphine 10 5
Bupropion 1 1 Naproxen 1 0
Bupropion metabolites 1 1 n-Desmethyltramadol 1 1
Carisoprodol 1 1 Nordazepam 9 6
Chlordiazepoxide 3 3 Norfluoxetine 1 1
Chlorpromazine 1 1 Norpromethazine 1 1
Chlorpheniramine 2 2 Nortriptyline 5 4
Citalopram 6 6 Norvenlafaxine 2 1
Chlorpheniramine 1 1 O-desmethyltramadol 2 2
Cocaethylene 2 2 Olanzapine 2 2
Codeine 3 3 Oxycodone 6 5
Cyclobenzaprine 2 1 Oxymorphone 3 3
Desmethylcitalopram 1 0 Paroxetine 1 0
Desmethylvenlafaxine 1 0 Phenytoin 2 0
Dextromethorphan 4 4 Promethazine 2 1
Diazepam 9 6 Propranolol 1 1
Dihydrocodeine 4 3 Quetiapine 3 3
Diphenhydramine 11 11 Quetiapine metabolites 6 5
Diphenhydramine metabolite 2 2 Quinine 1 0
Doxylamine 5 5 Sertraline 3 2
Fentanyl 2 2 Tapentadol 1 1
Fluconazole 2 2 Topiramate 2 2
Fluoxetine 4 4 Tramadol 2 2
Gabapentin 7 7 Trazodone 12 11
Haloperidol 1 0 Trihexyphenidyl 1 0
Hydrocodone 6 5 Trimethoprim 1 1
Hydromorphone 1 1 Venlafaxine 3 3
Ibuprofen 2 0 Zolpidem 2 1
Levamisole 2 2 Zopiclone 2 1
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Third, the gabapentin QC failed to bewithin the 20%CVof the target
(Supplementary Table II), indicating that quantitation for this drug
was not optimal and in need of additional investigation.
Our results are consistent with those of other investigators (3), sug-
gesting that vitreous humor can be an alternative matrix for qualitative
postmortem drug screening. Although some of the drugs were difficult
to identify, the vast majority of drugs identified in blood were also
found in vitreous fluid.
Supplementary data
Supplementary data are available at Journal of Analytical Toxicology
online.
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